PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement

Blood

Volumn 122, Issue 1, 2013, Pages 61-67

  Khan, Anjum Bashir ^a   Barrington, Sally Fiona ^a   Mikhaeel, Nabegh George ^a   Hunt, Alesia Abigael ^a   Cameron, Laura ^a   Morris, Tim ^b   Carr, Robert ^c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; FLUORODEOXYGLUCOSE; METHOTREXATE; RITUXIMAB;

ADULT; AGED; BONE MARROW BIOPSY; BONE MARROW DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GENE REARRANGEMENT; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; OVERALL SURVIVAL; PET SCANNER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; ARTICLE; BIOPSY; BONE MARROW; ILIAC BONE; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RADIOGRAPHY; RETROSPECTIVE STUDY; RISK FACTOR; SCINTISCANNING; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BONE MARROW; FEMALE; HUMANS; ILIUM; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84883710608     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-473389     Document Type: Conference Paper

References (31)

1. Morra E, Lazzarino M, Castello A, et al. Bone marrow and blood involvement by non-Hodgkin's lymphoma: a study of clinicopathologic correlations and prognostic significance in relationship to the Working Formulation. Eur J Haematol. 1989;42(5): 445-453. (Pubitemid 19150280)
2. Conlan MG, Bast M, Armitage JO, Weisenburger DD; Nebraska Lymphoma Study Group. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. J Clin Oncol. 1990;8(7):1163-1172. (Pubitemid 20195626)
3. Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol. 2006;76(6): 473-480.
4. Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer. 2004;91(5):850-854. (Pubitemid 39273774)
5. Raanani P, Shasha Y, Perry C, et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol. 2006;17(1):117-122. (Pubitemid 43033850)
6. Kwee TC, Kwee RM, Nievelstein RAJ. Imaging in staging of malignant lymphoma: a systematic review. Blood. 2008;111(2):504-516.
7. Elstrom RL, Leonard JP, Coleman M, Brown RK. Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol. 2008;19(10):1770-1773.
8. Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29(11):1452-1457.
9. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91(9): 3340-3346. (Pubitemid 28193885)
10. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011; 29(14):1844-1854.
11. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101(10):3875-3876. (Pubitemid 36857861)
12. Schaefer NG, Strobel K, Taverna C, Hany TF. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2007;34(1):60-67. (Pubitemid 44885555)
13. Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51(1): 25-30.
14. El-Galaly TC, d'Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012;30(36):4508-4514.
15. Kumar A, Vanderplas A, LaCasce AS, et al. Lack of benefit of central nervous prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012;118(11):2944-2951.
16. Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom? Blood Rev. 2012;26(3):97-106.
17. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896-3902.
18. Lee K-W, Yi J, Choi IS, et al. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement. Ann Hematol. 2009;88(9): 829-838.
19. Hofman MS, Smeeton NC, Rankin SC, Nunan T, O'Doherty MJ. Observer variation in interpreting 18F-FDG PET/CT findings for lymphoma staging. J Nucl Med. 2009;50(10):1594-1597.
20. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48(12):1503-1510. (Pubitemid 26035533)
21. Royston P, Sauerbrei W. Multivariable Model-Building: A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Modelling Continuous Variables. Chichester, UK: Wiley; 2008.
22. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273-2279.
23. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533-3537.
24. Elstrom RL, Tsai DE, Vergilio JA, Downs LH, Alavi A, Schuster SJ. Enhanced marrow [18F] fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow. Clin Lymphoma. 2004;5(1):62-64. (Pubitemid 39136445)
25. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a metaanalysis. J Nucl Med. 2005;46(6):958-963. (Pubitemid 43733510)
26. Hodges GF, Lenhardt TM, Cotelingam JD. Bone marrow involvement in large-cell lymphoma. Prognostic implications of discordant disease. Am J Clin Pathol. 1994;101(3):305-311. (Pubitemid 24089577)
27. Chen YK, Yeh CL, Tsui CC, Liang JA, Chen JH, Kao CH. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clin Nucl Med. 2011;36(7): 553-559.
28. Pelosi E, Penna D, Douroukas A, et al. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. Q J Nucl Med Mol Imaging. 2011;55(4):469-475.
29. Paone G, Itti E, Haioun C, et al. Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate. Eur J Nucl Med Mol Imaging. 2009;36(5):745-750.
30. Ghesquières H, Berger F, Felman P, et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol. 2006;24(33):5234- 5241. (Pubitemid 46631367)
31. Cheson BD. Hodgkin lymphoma: protecting the victims of our success. J Clin Oncol. 2012;30(36): 4456-4457.